Florida Attorney General Sues Pfizer for 'Misleading' COVID-19 Vaccine Safety Claims
Florida Attorney General James Uthmeier has filed a lawsuit against Pfizer Inc. and CEO Albert Bourla, accusing them of deceptive practices regarding the COVID-19 vaccine. The suit alleges Pfizer concealed critical safety risks, including links to myocarditis and strokes, and made unverified claims about the vaccine's ability to prevent transmission. The Attorney General further claims that Pfizer spent over $10 billion on advertising to generate demand, leading to over $80 billion in sales, while actively suppressing opposing views.
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Moderna's stock surged 8% as the company approaches the full readout of its Phase 3 melanoma vaccine trial at ESMO Madrid. The stock's year-to-date performance has been exceptional, driven by the anticipation of this data, making any negative findings a potential risk for a steep selloff. Meanwhile, BioNTech saw a slight gain, while Pfizer experienced a slip, reflecting their respective proximities to a personalized cancer vaccine breakthrough.
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Moderna's stock surged 8% to $205, reflecting investor anticipation of a positive full Phase 3 melanoma vaccine readout at ESMO Madrid. BioNTech also saw a modest gain, while Pfizer slipped, indicating market sensitivity to each company's proximity to a personalized cancer vaccine breakthrough. Analysts caution that Moderna's significant year-to-date run means any disappointment in the data could lead to a sharp selloff.
Twist Bioscience stock hits 52-week high at 200.49 USD
Twist Bioscience (TWST) stock reached a new 52-week high of $200.49, currently trading at $200.95 with a market capitalization of $12.28 billion. The company has seen a 495% year-to-date surge and a 507% increase over the past year, although InvestingPro data suggests the stock is overvalued. Recent developments include a partnership with Lilly TuneLab for antibody characterization and a prospectus supplement for share resale, alongside mixed analyst ratings and short-seller skepticism regarding AI claims.
Vaxcyte rises as pneumococcal shot establishes ‘new competitive moat’ vs. Pfizer, Merck
Vaxcyte's investigational pneumococcal conjugate vaccine, VAX-31, has shown "near best-case scenario" data in a Phase 3 trial, exceeding expectations and positioning the company to challenge Pfizer and Merck in the $8 billion market. The trial demonstrated VAX-31's non-inferiority to existing vaccines and superiority on three unique serotypes, leading to a significant surge in Vaxcyte's share price. Analysts believe VAX-31 sets a new competitive standard, potentially offering the broadest protection against pneumococcal disease.
Alector grants Genentech rights to GCase enzyme replacement therapy
Alector Inc. has granted Genentech Inc. exclusive global licensing rights for its AL-050 program, a brain-penetrant engineered glucocerebrosidase (GCase) enzyme replacement therapy. This preclinical therapy is aimed at neurological/psychiatric conditions. The agreement allows Genentech to develop and commercialize the program worldwide.
Vaxcyte Stock Hits New 52-Week High - Here’s Why
Vaxcyte Inc. (NASDAQ: PCVX) stock surged by over 56% in premarket trading, reaching a new 52-week high after announcing positive topline results from its Phase 3 OPUS-1 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine. The vaccine met all primary immunogenicity endpoints, demonstrating noninferiority to existing vaccines from Pfizer and Merck, and showed a strong safety profile. These findings will support an upcoming Biologics License Application submission to the U.S. FDA, with further trial results expected in 2027.
Pfizer’s Turnaround Could Be Bigger Than Investors Think, Set For 20% Upside
Pfizer is showing strong potential for a significant turnaround, with 24/7 Wall St. rating it a BUY with a $33 price target, implying a 20% upside from its current $27.60 share price. The company has delivered ten consecutive earnings beats, and its pipeline, particularly the Metsera GLP-1 deal for obesity and advancements in oncology, is expected to drive future growth despite a shrinking COVID-related revenue. Investors are encouraged by Pfizer's valuation at 10x forward earnings and a 6% dividend yield, positioning it as a value play among its peers.
Audited Vidya accounts for 2024 and 2025 join Processa (PCSA)'s acquisition update.
Processa Pharmaceuticals (PCSA) has updated its acquisition details for Vidya Therapeutics, including Vidya's audited financial statements for 2024 and 2025 and unaudited interim statements for the first half of 2026. This amendment is part of the 8-K filing related to Processa's acquisition of Vidya, which closed on July 28, 2026, bringing the BTK inhibitor VT7208 into Processa's pipeline. The updated filing provides financial context for the acquisition and Processa's pro forma financial information, highlighting the company's focus on developing VT7208 for food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis.
Valneva Stock Forecast | EMA Validates Lyme Vaccine Application
The European Medicines Agency has validated the marketing-authorisation application for Valneva and Pfizer’s Lyme disease vaccine candidate. Valneva's stock has been influenced by regulatory progress and financial performance, including a widened net loss in the first half of 2026, though a capital raise has improved cash reserves. Analyst price targets for Valneva vary, reflecting different assumptions about regulatory approval and future vaccine revenue.
Precision Medicine: A 62-Asset Test Of Whether The Vertex Model Travels Beyond Oncology
In Vivo has identified 62 non-oncology precision medicine assets currently undergoing clinical trials, with gene therapy being the predominant intervention. This analysis explores whether the successful Vertex Pharmaceuticals model, known for its precision medicine approach in oncology, can be effectively applied to other therapeutic areas. The article examines the implications of this finding for the broader life sciences industry.
Pfizer Inc. Stock Grades | PFE
This article provides detailed stock information for Pfizer Inc. (PFE), including its current stock price, market performance metrics, analyst ratings, and key financial data. It also outlines the company's business activities as a global biopharmaceutical company and compares its performance with peer companies in the industry.
Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval
Invivyd's VYD2311 Phase III LIBERTY study successfully met its safety and tolerability objectives, demonstrating fewer adverse events compared to Pfizer-BioNTech's COMIRNATY vaccine. The company plans to seek FDA accelerated approval for VYD2311 based on serum virus-neutralizing antibody titers, with further safety and immunogenicity data expected from the delayed DECLARATION study to support a biologics license application. Invivyd also noted that the combination of VYD2311 and vaccination improved vaccine tolerability without reducing the immune response.
Lilly and Novo share GLP-1 longevity data
Novo Nordisk and Eli Lilly presented early, unpublished data at ARDD 2026 regarding the longevity potential of GLP-1 receptor agonists. Novo's data suggested semaglutide could lead to 1.9 years of additional life expectancy and showed reduced biological aging, while Lilly's epigenetic sub-study on tirzepatide indicated a slower pace of biological aging. Both companies acknowledged the preliminary nature of their findings but are building an evidence base that GLP-1s could function as longevity drugs.
NOVARTIS AG N (NOTA.F) Q2 FY2026 earnings call transcript
Novartis reported strong Q2 FY2026 performance, with net sales up 1% and core operating income flat, driven by key growth brands like KISQALI, Cosentyx, and Scemblix. The company reaffirmed its full-year 2026 guidance, expecting low single-digit net sales growth and a low single-digit decline in core operating income. Novartis highlighted significant pipeline advancements, including updated KISQALI data, progress in rare disease programs like del-brax, and anticipated regulatory milestones and readouts for various assets in the second half of the year.
AstraZeneca PLC (ZEG.SG) stock price, news, quote and history
This article provides a detailed financial overview of AstraZeneca PLC (ZEG.SG) including its stock price, trading data, and key metrics. It highlights the stock's performance with its current price at 139.30 EUR, a slight decrease of 0.68%, and offers various financial statistics such as previous close, day's range, volume, and upcoming earnings date. The page also features related stock listings and market data.
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
This article compares AbbVie (ABBV) and Bristol Myers (BMY), two pharmaceutical companies that have recently navigated or are about to navigate patent expirations. While AbbVie successfully replaced its blockbuster drug Humira with Skyrizi and Rinvoq, showing strong growth and operating margins, Bristol Myers is highlighted as a cheaper stock with better net margins and return on equity, despite facing its own upcoming patent cliff. The analysis concludes that AbbVie is the better business, but Bristol Myers is the better-priced stock, offering a higher yield and lower forward multiple.
Eli Lilly & Co (LLY) Gets a Buy from RBC Capital
RBC Capital analyst Trung Huynh maintained a Buy rating on Eli Lilly & Co (LLY) with a price target of $1,500.00, following the company's strong Q2 earnings report. Another firm, TD Cowen, also reiterated a Buy rating with a $1,250.00 price target. The analyst consensus for Eli Lilly & Co is a Strong Buy, with a collective price target suggesting an 18.64% upside.
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
This article compares AbbVie (ABBV) and Bristol Myers Squibb (BMY), two pharmaceutical companies that have both faced the challenge of replacing blockbuster drugs. While AbbVie has successfully replaced Humira and shows stronger operational growth, Bristol Myers is presented as the better-priced stock, trading at a lower multiple with higher net margins and dividend yield. The analysis concludes that while AbbVie is a better business, Bristol Myers offers a more attractive investment at its current valuation.
Pyxis Oncology, Inc. (PYXS) Stock Price, News, Quote & History
This Yahoo Finance page provides a comprehensive overview of Pyxis Oncology, Inc. (PYXS), including its current stock price, financial summary, key statistics, and company profile. It highlights the company's clinical-stage development of therapeutics for solid tumors, detailing its lead product candidates and partnerships. The article also presents performance data, earnings trends, analyst ratings, and valuation measures for investors.
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
This article compares two healthcare giants, Novo Nordisk and Pfizer, to determine which is a better investment in 2026. It analyzes their financials, risk profiles, and valuations, concluding that Pfizer, despite not being a high-growth stock, presents a better buy due to its current valuation and improving net income.
PFIZER INC (PFE-USD.SW) interactive stock chart – Yahoo Finance
This Yahoo Finance page provides an interactive stock chart for PFIZER INC (PFE-USD.SW), displaying its current stock price and performance. It also aggregates recent news articles related to Pfizer, highlighting its drug developments, stock performance, and legal matters. The page serves as a hub for investors to quickly access financial data and news regarding Pfizer.
AbbVie joins US government pilot to test drug discount rebates
AbbVie will participate in a US government pilot program to test a new rebate system for discounted medicines under the 340B program, starting January 1, 2027. This initiative aims to improve pricing transparency and prevent duplicate discounts as new Medicare-negotiated drug prices take effect. Other major pharmaceutical companies like Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are also part of this federal pilot.
AbbVie joins US government pilot to test drug discount rebates
AbbVie will participate in a U.S. government pilot program starting January 1, 2027, to test a new rebate system for discounted medicines under the 340B program. This initiative aims to improve pricing transparency and prevent duplicate discounts for drugs like Imbruvica, Linzess, and Vraylar, especially as new Medicare-negotiated drug prices take effect. Other major pharmaceutical companies like Amgen, AstraZeneca, Pfizer, and Bristol Myers Squibb are also approved for this federal pilot.
Pfizer’s TACTIVE-U Breast Cancer Combo Trial Reaches Key Milestone
Pfizer Inc. (PFE) has provided an update on its TACTIVE-U Sub-Study C, a Phase 1b/2 clinical trial evaluating a daily oral combination of vepdegestrant and samuraciclib for advanced estrogen receptor-positive breast cancer. The study, which began in October 2023, is now listed as completed with the latest update on September 29, 2026, indicating that key data are being analyzed. This development is significant for investors and Pfizer's partners, as positive data could strengthen Pfizer’s position in breast cancer therapies and influence regulatory and strategic decisions.
Pfizer says phase 3 data buoys Litfulo as a vitiligo treatment
Pfizer announced positive phase 3 results for its alopecia drug Litfulo (ritlecitinib) as a treatment for vitiligo. The studies showed significant improvements in facial and total body repigmentation in vitiligo patients after one year of treatment. This data suggests Litfulo could be a promising new option for vitiligo.
BMO most bullish on Merck’s, bearish on BMS’ plans to contend with patent cliffs
BMO Capital Markets is more optimistic about Merck's strategy to offset the upcoming patent cliff for Keytruda than it is about Bristol Myers Squibb's efforts to replace lost revenue from Opdivo and Eliquis. Merck has prepared a strong pipeline of growth products, including an mRNA cancer vaccine, Winrevair, and sac-TMT, which are expected to generate significant sales. In contrast, BMS's replacement assets, such as Cobenfy and milvexian, are considered riskier and have faced challenges, making BMO less confident in BMS's ability to stabilize revenue.
Agios' Growth Story Hinges on Mitapivat's Commercial Expansion
Agios Pharmaceuticals is heavily relying on its lead therapy, mitapivat, for commercial growth as it expands into multiple blood disorders, including pyruvate kinase deficiency and thalassemia, and seeks approval for sickle cell disease. Despite strong early commercial performance for Pyrukynd and Aqvesme, the company faces significant competition from other pharmaceutical giants like Novo Nordisk and Bristol Myers Squibb in its target markets. The discontinuation of a next-generation growth driver, tebapivat, further underscores mitapivat's critical role in Agios's near-to-medium-term success.
Samsung Bioepis, Teva expand biosimilar partnership with Fasenra, Ilaris candidates
Samsung Bioepis and Teva Pharmaceutical Industries have expanded their biosimilar partnership to include two new candidates, SB41 (referencing Fasenra) and SB44 (referencing Ilaris). Under the agreement, Samsung Bioepis will handle development, regulatory approvals, and manufacturing, while Teva will commercialize the products in the U.S., Europe, and Canada. This collaboration builds on their existing partnership, which includes Epysqli and Opuviz.
Sanofi, Regeneron broaden alliance to find their next Dupixent
Sanofi and Regeneron have expanded their long-standing alliance with a $1 billion upfront payment to develop new long-acting antibody drugs, targeting the same interleukins as their blockbuster Dupixent. This collaboration aims to create "next-generation" immunology medicines, addressing concerns about Dupixent's upcoming patent expirations and potentially setting the stage for future partnerships. While the deal is seen as positive for Regeneron, the new drugs are still in early development, and their differentiation in a crowded market remains to be proven.
Pfizer Inc. (PFE) Options Chain
This article displays the options chain for Pfizer Inc. (PFE), detailing call and put options with an expiration date of January 19, 2029. It includes various strike prices, last trade dates and times, last prices, bid/ask, change, percentage change, volume, open interest, and implied volatility for both in-the-money calls and puts. The data provided is delayed by 15 minutes.
Key facts: Pfizer Inc. positive tilrekimig Phase 2; Florida AG suit
Pfizer reported positive Phase 2 data for its drug tilrekimig, showing strong response rates and itch relief, despite a slight dip in its stock price. Separately, the Florida Attorney General has sued Pfizer and its CEO over alleged misstatements regarding the COVID-19 vaccine, seeking fines and injunctive relief, a claim Pfizer disputes.
Nektar Discloses Phase 2b Data for REZPEG in Severe Alopecia Areata
Nektar Therapeutics announced Phase 2b data for rezpegaldesleukin (REZPEG) in severe alopecia areata from its REZOLVE-AA trial. REZPEG works by stimulating regulatory T-cells, offering a mechanistically distinct approach compared to existing JAK inhibitors. The data release included an investor presentation, with the primary endpoint being the mean percentage reduction from baseline in scalp hair loss severity.
GSK PLC ADR Advanced Charts | GSK
This article provides advanced chart information for GSK PLC ADR (GSK), including real-time stock quotes, analyst ratings, and key financial metrics. It details the company's profile as a healthcare firm focusing on pharmaceutical medicines, vaccines, and consumer healthcare products. The page also lists peer comparisons and disclaimers about data sources and accuracy.
Edwards Lifesciences wins FDA approval for AUTUS
Edwards Lifesciences has received FDA approval for its AUTUS pediatric pulmonary valve, designed for children with congenital pulmonary valve disease. This innovative valve can be surgically implanted and later expanded via a catheter as the child grows, potentially reducing the need for multiple surgeries. The FDA's approval was based on a 62-child study, noting the valve's early performance but also flagging longer-term risks.
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas, Inc. announced that novel biomarker data from its Phase 1 clinical trial for ARV-102, an investigational PROTAC LRRK2 degrader for Parkinson's disease, will be presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®. The data will be shared in both oral and poster presentations, detailing oculomotor and biomarker findings. ARV-102 is designed to cross the blood-brain barrier and target LRRK2, a protein implicated in Parkinson's disease and progressive supranuclear palsy.
A CFO who led finance work on a drug company sale of up to $1.1 billion will join Achieve as CFO.
Achieve Life Sciences has appointed Benjamin Halladay as its new Chief Financial Officer, effective October 5, 2026, succeeding Mark Oki. Halladay brings over 15 years of financial management experience, including a recent role as CFO of Esperion Therapeutics, where he managed a significant company sale. His expertise in commercial pharma and business development is expected to support Achieve's potential commercialization of cytisinicline for nicotine dependence.
Uthmeier alleges Pfizer misled Florida about its COVID vaccine’s safety
Florida Attorney General James Uthmeier has filed a lawsuit against Pfizer Inc., accusing the company of unfair and deceptive marketing regarding its COVID-19 vaccine. The suit, which also names CEO Albert Bourla, seeks monetary damages and an injunction, alleging Pfizer misled consumers and suppressed dissent while being aware of undisclosed safety risks. Pfizer denies the allegations, stating its vaccine representations were accurate and science-based, and that the vaccine has a favorable safety profile and has saved countless lives.
Uthmeier alleges Pfizer misled Florida about its COVID vaccine’s safety
Florida Attorney General James Uthmeier has filed a lawsuit against Pfizer Inc., alleging unfair and deceptive marketing practices regarding its COVID-19 vaccine. The suit claims Pfizer misled Florida consumers about the vaccine's safety and efficacy while potentially concealing data on serious risks. Pfizer denies the allegations, stating its representations were accurate and science-based, and stands by the safety and efficacy of its vaccine.
Pfizer Says Eczema Drug Shows Significant Skin Clearance
Pfizer announced positive Phase 2 results for its eczema drug, tilrekimig (PF-07275315), demonstrating significant skin clearance in adults with moderate-to-severe atopic dermatitis. The trial met its primary endpoint, showing increased EASI-75 achievement across various dosing regimens compared to placebo. Tilrekimig is a trispecific antibody designed to inhibit type 2 inflammation and was well-tolerated in the study.
Medpace Holdings Insider Sold Shares Worth $30,320,929, According to a Recent SEC Filing
An insider at Medpace Holdings has sold shares totaling $30,320,929, as reported in a recent SEC filing. This transaction is part of a series of insider share sales from the company, with previous sales ranging from hundreds of thousands to millions of dollars. Medpace Holdings is a global clinical contract research organization specializing in Phase I-IV clinical development services for the biotechnology, pharmaceutical, and medical device industries.
Pfizer Sued By Florida AG Over its Covid-19 Vaccine Marketing
Florida Attorney General James Uthmeier has filed a lawsuit against Pfizer Inc. and its CEO, Albert Bourla, alleging that they misled the public about the safety of its Covid-19 vaccine. The lawsuit claims Pfizer concealed safety risks for pregnant women, known adverse effects, and the risk of myocarditis. This legal action aligns with broader Republican efforts to scrutinize vaccine safety and pandemic protocols.
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Arvinas, Inc. will present novel biomarker data from a Phase 1 clinical trial of its investigational drug, ARV-102, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders. ARV-102 is a PROTAC LRRK2 degrader designed to treat Parkinson's disease. The data will be shared in both oral and e-poster presentations, detailing oculomotor and biomarker findings from the study.
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
Moderna's stock surged 3% despite a Citigroup downgrade to "Sell" with an $80 price target, indicating investor confidence in its cancer vaccine pipeline outweighs valuation concerns. BioNTech saw a smaller gain, while Pfizer's stock slipped, highlighting Moderna's isolated positive performance. The market is keenly awaiting Moderna's complete melanoma trial data in late October, which could determine the broader reach of its mRNA platform.
Pfizer Says Eczema Drug Shows Significant Skin Clearance
Pfizer announced positive Phase 2 results for its eczema drug, tilrekimig, showing significant skin clearance in adults with moderate-to-severe atopic dermatitis. The drug met its primary endpoint, with a high percentage of participants achieving EASI-75 across various dosing regimens. Tilrekimig, a potential first-in-class trispecific antibody, also demonstrated good safety and tolerability.
Pfizer presents tilrekimig data while Pfizer stock stays near its prior close
Pfizer (PFE) presented positive detailed Phase 2 results for its inflammation and immunology drug, tilrekimig, showing 61.00 percent EASI-75 at Week 16 for the 200 mg monthly dose in atopic dermatitis. The company also reported strong Q2 2026 revenue of USD 15.03 billion, beating estimates, and raised the lower end of its fiscal 2026 revenue guidance. Pfizer stock remained near its prior close on October 1, 2026, trading at EUR 25.19, with its next earnings report scheduled for November 3, 2026.
Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Achieve Life Sciences has appointed Benjamin Halladay as its new Chief Financial Officer, effective October 5, 2026. Halladay brings extensive experience from commercial-stage pharmaceutical companies, including Esperion Therapeutics and Pfizer Inc., which will be crucial as Achieve prepares for the potential commercialization of cytisinicline. He will be responsible for the company's financial strategy, accounting, investor relations, and IT functions.
Cantor Fitzgerald reiterates Dyne Therapeutics stock rating
Cantor Fitzgerald reiterated an Overweight rating on Dyne Therapeutics (NASDAQ:DYN) after the biotech company released additional one-year data from its Phase 1/2 ACHIEVE study for DM1 patients. Despite a 17% year-to-date stock decline, shares are up 28% over the past year. The company's financial position is strong, with more cash than debt, as it progresses towards regulatory milestones, though some analysts have adjusted price targets due to Novartis's recent trial failure in a similar study.
Pfizer eczema drug succeeds in mid-stage study (PFE:NYSE)
Pfizer's experimental eczema drug, tilrekimig, showed strong skin clearance in a mid-stage Phase 2 trial for adults with moderate-to-severe atopic dermatitis. The trispecific antibody demonstrated significant efficacy, indicating potential as a new treatment for the condition.
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Unicycive Therapeutics, a clinical-stage biotechnology company, announced the appointment of Meredith Manning, M.B.A., to its Board of Directors. Manning brings over 25 years of global biopharmaceutical experience, including leadership roles in commercialization and product launches at companies like Soleno Therapeutics and PharmaEssentia Corporation. Her expertise is expected to be invaluable as Unicycive advances its lead investigational treatment, oxylanthanum carbonate, towards potential approval and prepares for commercial-stage growth.
